Scientists Finally Agree On What Psychedelics Do To The Brain

Five Psychedelics, One Brain Pattern

Magic mushrooms, LSD, and mescaline are very different drugs. But inside the brain, they appear to be doing something remarkably similar.

A sweeping new brain-imaging study, published in Nature Medicine, pooled data from 267 participants across five countries to map what happens inside the human brain during a psychedelic experience. Researchers examined psilocybin (the active compound in magic mushrooms), LSD, mescaline, DMT, and ayahuasca. Despite their chemical differences, all five drugs triggered the same core pattern: regions responsible for inward-focused thinking and planning suddenly began communicating with regions that handle basic sensory tasks like seeing and moving. In a normally functioning brain, those systems largely keep to themselves.

More than 400 clinical trials are currently testing psychedelic therapy for conditions ranging from depression to alcoholism, yet scientists have spent years arguing about what these drugs actually do inside the brain. Findings from individual labs have been scattered and sometimes contradictory. This study, conducted by an international group called the BOLD Psychedelic Consortium, reprocessed raw brain-scan data from 11 separate datasets through a single uniform analysis pipeline, helping reduce inconsistencies that had muddied earlier comparisons.

Equally notable is what the researchers did not find. Earlier studies reported that psychedelics cause widespread breakdown within brain networks. Under the stricter statistical lens used here, that picture appears weaker and less consistent than previously claimed.

How Psychedelics Shift Brain Communication

Think of the brain as a collection of specialized neighborhoods. Some handle raw sensory input. Others manage abstract operations like self-reflection, planning, and memory. In everyday life, a firm pecking order governs how these neighborhoods interact, with sensory regions feeding information upward for higher-order regions to interpret.

Psychedelics appear to flatten that pecking order.

Across all five drugs and all 11 datasets, the most consistent finding was a surge in communication between networks involved in abstract thinking and those that process vision and body movement. Brain regions handling daydreaming and planning were suddenly in close contact with those handling raw sensory experience. Researchers used a statistical approach that asks not just whether an effect occurred, but how confident we can be that it is real and how large it actually is, a key safeguard against overstating results.

Psychedelics and the Brain’s Deep Structures

Beyond the brain’s outer surface, two deeper structures, the caudate and putamen, showed consistently increased communication with sensory networks across drugs. Both act as a switchboard linking what a person perceives with how they respond.

Another structure, the thalamus, has long been theorized as central to psychedelic brain changes. Early analyses here did show increased thalamic coupling with sensorimotor networks under certain conditions. Under the stricter statistical test, those effects were less consistent and often weaker than expected across drugs and datasets, raising questions about how central the thalamus truly is compared to the caudate and putamen.

Some networks showed modestly reduced internal connectivity under psychedelics, particularly sensory and motor networks, but the effect varied considerably across drugs and analysis methods, and many changes could not be confidently distinguished from zero.

Why Each Psychedelic Produces a Different Brain Fingerprint

LSD and psilocybin produced virtually identical brain signatures, consistent with their similar chemistry and the similar experiences people report. Mescaline followed a broadly comparable pattern with more selective effects. DMT appeared to produce the strongest overall changes in brain connectivity, though a sample size of just 16 participants limits firm conclusions.

Ayahuasca stood out as the clearest outlier. Despite containing DMT as its active ingredient, it showed a connectivity profile that did not match the other drugs. Researchers attributed this partly to its pharmacological complexity: ayahuasca contains additional compounds that alter how DMT is processed in the body, and its dataset of just nine participants made direct comparison difficult.

With hundreds of clinical trials underway, mapping what these drugs reliably do to the brain carries real stakes. A clearer picture of shared and drug-specific brain effects could eventually help clinicians predict which patients will respond to treatment, choose the right drug and dose, or pursue therapies targeting the same brain circuits without a full psychedelic experience. What the study cannot answer is whether the sensory-to-abstract blending is driven top-down or bottom-up, and variability in dosage, timing, and administration likely influenced results across the 11 datasets.

Psychedelics temporarily reorganize brain activity, dissolving functional boundaries between sensory machinery and higher-order thinking systems while recruiting deep-brain switching stations in the process. Whether that reorganization drives their therapeutic promise remains an open question, but researchers now have a shared map to follow.

---

Disclaimer: This article is based on an observational brain-imaging study conducted in healthy adults. All brain changes described reflect acute effects during drug exposure and do not indicate long-term or permanent changes. Psychedelic substances remain controlled under federal law in the United States. Nothing in this article should be construed as medical advice or an endorsement of psychedelic drug use.

---